EDP Sciences logo
rechercher
Menu
Accueil Tous les numéros Numéro 17 (Juin 2018) Cah. Myol., 17 (2018) 5-10 References
Open Access
Issue
Cah. Myol.
Number 17, Juin 2018
Page(s) 5 - 10
Section Historique / Historical notes
DOI https://doi.org/10.1051/myolog/201817002
Published online 6 juin 2018
  1. https://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProduct-Designation/UCM517741.pdf [Google Scholar]
  2. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:pdf [Google Scholar]
  3. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=FR [Google Scholar]
  4. https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_fr.pdf [Google Scholar]
  5. Haffner ME. History of orphan drug regulation-United States and beyond. Clin Pharmacol Ther 2016; 100: 342–343.www.wileyonlinelibrary/cpt. [CrossRef] [PubMed] [Google Scholar]
  6. Mikami K. Orphans in the market: the history of orphan drug policy, Social History of Medicine November 2017, published online. https://doi.org/10.1093/shm/hkx098. [Google Scholar]
  7. European medicines agency. 28February 2018, EMA/ 551338/2017. Rare diseases, orphan medicines getting the facts straight. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2018/02/WC500244578.pdf. [Google Scholar]
  8. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today 2013; 18: 163–172. [CrossRef] [PubMed] [Google Scholar]
  9. Eurordis 2018. Eurordis therapeutic report. March 2018, issue 3. [Google Scholar]
  10. Kapur AK. The impact of orphan drug incentives on innovation and pricing in niche therapeutic markets: a systematic review of the littérature. Value in Health 2012; 15: A277–575. [Google Scholar]
  11. Vassal G, Kearns P, Blanc P, et al. Orphan drug regulation: a missed opportunity for children and adolescents with cancer. Eur JCancer 2017; 84: 149–158. [CrossRef] [Google Scholar]
  12. Wechsler J. Biotech innovation boosts orphan drug development. Economic incentives and regulatory flexibility can spur development of treatments for small patient populations. BioPharm International 2008; 21: (7). [Google Scholar]
  13. European public health alliance (EPHA). The top 5 issues in medicines policy. Analysis. January 2018. [Google Scholar]
  14. Tiennot Herment L. Le chemin du médicament dans les maladies neuromusculaires : une nouvelle aventure. . Cah Myol 2017; 15: 3. https://www.cahiers-myologie.org/articles/myolog/full_html/2017/01/myolog201715p3/myolog201715p3.html. [CrossRef] [Google Scholar]
  15. Rigal Loïc. Le droit des médicaments orphelins en Europe. Thèse de doctorat de droit public. Université Paris Descartes. École doctorale Sciences juridiques, politiques, économiques et de gestion. Institut Droit et Santé - Inserm UMR S 1145, 2017. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.